Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
JCO Precis Oncol. 2023 Sep;7:e2300338. doi: 10.1200/PO.23.00338.
JCO Precis Oncol. 2023.
PMID: 38039432
Free PMC article.
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.
Knappskog S, et al. Among authors: yndestad s.
Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.
Mol Oncol. 2015.
PMID: 26004085
Free PMC article.
Item in Clipboard
Impaired lymphatic function accelerates cancer growth.
Steinskog ES, Sagstad SJ, Wagner M, Karlsen TV, Yang N, Markhus CE, Yndestad S, Wiig H, Eikesdal HP.
Steinskog ES, et al. Among authors: yndestad s.
Oncotarget. 2016 Jul 19;7(29):45789-45802. doi: 10.18632/oncotarget.9953.
Oncotarget. 2016.
PMID: 27329584
Free PMC article.
Item in Clipboard
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.
Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lønning PE, Eikesdal HP.
Yndestad S, et al.
Breast Cancer Res Treat. 2017 May;163(1):177-190. doi: 10.1007/s10549-017-4160-5. Epub 2017 Feb 17.
Breast Cancer Res Treat. 2017.
PMID: 28213783
Free PMC article.
Item in Clipboard
Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S, Austreid E, Svanberg IR, Knappskog S, Lønning PE, Eikesdal HP.
Yndestad S, et al.
Oncotarget. 2017 Jun 20;8(25):41227-41241. doi: 10.18632/oncotarget.17167.
Oncotarget. 2017.
PMID: 28476032
Free PMC article.
Item in Clipboard
Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer.
Yndestad S, Austreid E, Skaftnesmo KO, Lønning PE, Eikesdal HP.
Yndestad S, et al.
Mol Cancer Res. 2018 Jan;16(1):78-89. doi: 10.1158/1541-7786.MCR-17-0207. Epub 2017 Oct 11.
Mol Cancer Res. 2018.
PMID: 29021233
Item in Clipboard
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
Eikesdal HP, et al. Among authors: yndestad s.
Ann Oncol. 2021 Feb;32(2):240-249. doi: 10.1016/j.annonc.2020.11.009. Epub 2020 Nov 24.
Ann Oncol. 2021.
PMID: 33242536
Free article.
Clinical Trial.
Item in Clipboard
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development.
Nikolaienko O, Eikesdal HP, Ognedal E, Gilje B, Lundgren S, Blix ES, Espelid H, Geisler J, Geisler S, Janssen EAM, Yndestad S, Minsaas L, Leirvaag B, Lillestøl R, Knappskog S, Lønning PE.
Nikolaienko O, et al. Among authors: yndestad s.
Genome Med. 2023 Dec 6;15(1):104. doi: 10.1186/s13073-023-01262-8.
Genome Med. 2023.
PMID: 38053165
Free PMC article.
Item in Clipboard
Cite
Cite